Janux Therapeutics opens Phase 1 combo trial of JANX013 and JANX007 in mCRPCSep 10Trial updateJanux TherapeuticsJANX007
Janux reports Q2 2026 results, keeps prostate cancer and autoimmune programs on trackAug 6Quarterly updateJanux TherapeuticsJANX007
Sign inSign in